Covid-19 (Temas de Saúde Pública)
M-A | Pacientes psiquiátricos têm risco aumentado de hospitalização e morte por COVID-19.
26 Jul, 2021 | 10:20hComunicado de imprensa: Psychiatric patients at increased risk of COVID-19 hospitalization and mortality – European College of Neuropsychopharmacology
Estudo mostra que o teste de antígeno de fluxo lateral pode detectar, de modo rápido e acurado, a COVID-19 inicial em pacientes com sintomas gripais e pode ser uma alternativa plausível ao RT-PCR.
26 Jul, 2021 | 10:19hComunicado de imprensa: Lateral flow tests are 95% effective at detecting Covid-19 when used at the onset of symptoms – University of Oxford
Relacionado:
Rapid point-of-care tests for diagnosing COVID-19 infection: the latest Cochrane evidence
Comentário no Twitter (fio – clique para saber mais)
Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with RT-PCR in primary care (REAP-2)
Thread on today's @EDGEclinical paper, with some recommendations at the end for how we can improve UK testing. 🧵
— The Sharing Scientist (@ScienceShared) July 14, 2021
Vacinas contra COVID talvez cheguem aos países mais pobres somente em 2023 – “Especialistas afirmam que, em meio ao aumento da COVID na África, a promessa de vacinas vindo de nações mais ricas não é suficiente para acabar com a pandemia.”
26 Jul, 2021 | 10:15hCOVID vaccines to reach poorest countries in 2023 — despite recent pledges – Nature
OMS | Desigualdade vacinal prejudica a recuperação econômica global.
23 Jul, 2021 | 10:19hComunicado de imprensa: Vaccine inequity undermining global economic recovery – World Health Organization
Painel: Global Dashboard for Vaccine Equity
Comentários: Urgent need for COVID-19 vaccine equity – University of Oxford E COVID-19 Vaccine Inequity Undermines Global Economic Recovery – Health Policy Watch
Comentário no Twitter (fio – clique para saber mais)
COVID-19 vaccine inequity is undermining 🌍 economic recovery. 🆕WHO, @UNDP and @BlavatnikSchool Dashboard on #VaccinEquity finds that low-income countries would add $38B to their GDP forecast if they had the same vaccination rate as high-income countrieshttps://t.co/BsYF2eYL1G
— World Health Organization (WHO) (@WHO) July 22, 2021
Perspectiva | “Challenge Trials” com o SARS-CoV-2 (quando pessoas saudáveis são expostas deliberadamente ao virus, para fins de pesquisa) – Estabelecendo um modelo durante uma pandemia em evolução.
23 Jul, 2021 | 10:17hRelacionado: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (vários textos sobre o tema) E Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.
Como a variante Delta atinge sua disseminação ultrarrápida – “A carga viral é cerca de 1.000 vezes maior em pessoas infectadas com a variante Delta do que nos infectados com a cepa original do coronavírus, de acordo com estudo feito na China.”
23 Jul, 2021 | 10:15hHow the Delta variant achieves its ultrafast spread – Nature
O que são as variantes Delta, Gama, Beta e Alfa da Covid?
23 Jul, 2021 | 10:14hWhat are the Delta, Gamma, Beta and Alpha Covid variants? – BBC
Relacionado: Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”. E WHO renames COVID-19 variants with the Greek alphabet (i.e., Alpha, Beta, Gamma, etc), making them simple, easy to say and remember. The naming system aims to prevent calling COVID-19 variants by the places where they are detected, which is stigmatizing & discriminatory.
A variante Lambda: ela é mais infecciosa e escapa das vacinas? Virologista explica.
23 Jul, 2021 | 10:14hRelacionado: Lambda, the Newest WHO Variant of Interest, is Now in 29 Countries – Health Policy Watch
Estudo mostra que vacinas da AstraZeneca e da Pfizer são eficazes contra a variante Delta, mas são necessárias as duas doses.
22 Jul, 2021 | 13:08hComentários: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes E Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider
Relacionado: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. E Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. E Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
Comentário no Twitter
Public Health England's test-negative case-control study for Delta variant now in NEJM: over 14,000 people with Alpha, over 4,000 with Delta https://t.co/3l1QhKeXBT
Vax effectiveness against testing positive for Delta after 2 doses:
– BNT-Pfizer 88.0% (85-90)
– AZ 67.0% (61-72) pic.twitter.com/9UFy6CLSWw— Hilda Bastian, PhD (@hildabast) July 21, 2021
Anticorpos contra COVID-19 persistem por, pelo menos, 9 meses após a infecção – “98,8% das pessoas infectadas em fevereiro/março mostraram nível detectáveis de anticorpos em novembro.”
22 Jul, 2021 | 13:07hComunicado de imprensa: COVID-19 antibodies persist at least nine months after infection – Imperial College London
Estudo original: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications